BIOCYTOGEN PHARMA. H YC1 (I54) — Cash Flow Quality Index
BIOCYTOGEN PHARMA. H YC1 (I54) has a Cash Flow Quality Index of 2.14x as of December 2025. Operating cash flow of €370.25 Million exceeds net income of €173.20 Million, indicating high earnings quality where cash backs reported profits. Also explore I54 asset base for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BIOCYTOGEN PHARMA. H YC1 Cash Flow Quality Index (2024–2025)
Historical Cash Flow Quality Index for BIOCYTOGEN PHARMA. H YC1 across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check BIOCYTOGEN PHARMA. H YC1 (I54) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for BIOCYTOGEN PHARMA. H YC1 (2024–2025)
Year-by-year earnings quality comparison for BIOCYTOGEN PHARMA. H YC1. For live market cap and the full company financial profile, see I54 market cap.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.14x | €370.25 Million | €173.20 Million | ▼ -66.1% |
| 2024 | 6.30x | €211.25 Million | €33.54 Million | — |